ArticleClinical ophthalmology (Auckland, N.Z.)2021
Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits.
Article in Clinical ophthalmology (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Proliferative Diabetic Retinopathy Requiring Vitrectomy Over Clinic Management During COVID-19: Impact of Delayed Care.Korean journal of ophthalmology : KJO · 2023Article
- The negative impact of COVID-19 pandemic on age-related macular degeneration patients treated with intravitreal bevacizumab injections.International ophthalmology · 2022Article
- Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.Retina (Philadelphia, Pa.) · 2022Article
- Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Effects of COVID-19 on Intravitreal Injection Clinic After Lockdown.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- [Impact of the SARS-CoV-2 pandemic on diabetic macular edema and prognostic factors].Journal francais d'ophtalmologie · 2021Article
- Article
- The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment.Current diabetes reports · 2021Review
- Modifications of intravitreal injections in response to the COVID-19 pandemic.Journal of the Chinese Medical Association : JCMA · 2021Review
- Modeling the impact of COVID-19 on Retina Clinic Performance.BMC ophthalmology · 2021Article
- The Influence of COVID-19 Lockdown in Jordan on Patients with Diabetic Retinopathy: A Case-Control Study.Therapeutics and clinical risk management · 2021Article
- The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- The Impact of COVID-19 on US and International Retina Specialists, Their Practices, and Their Patients.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo determine secondary effects of the mandated COVID-19 pandemic closure period for elective treatment on non-elective, injection-based retina care and outcomes. PATIENTS AND
methodsIn this cross-sectional, retrospective analysis of a single-provider outpatient clinic across multiple satellites, consecutive patients returning for intravitreal injections (IVIs) of anti-vascular endothelial growth factor or corticosteroids were identified as "delayed" or "undelayed" during a six-week study interval during the COVID-19 pandemic that closely following a mandated period of prohibited elective encounters. A "delayed" encounter was defined as having a follow-up interval exceeding 33% of the recommended cycle. Patients seen for IVIs during the corresponding six-week interval a year previously were identified for study as pre-COVID-19 controls. Main outcome measures included best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) assessment based on findings of intraretinal or subretinal fluid consistent with new or recurrent neovascular events.
resultsThe study included 183 eyes of 144 patients who underwent IVI-based care from June 18, 2020, through August 7, 2020, compared to 193 eyes of 154 patients injected during the corresponding interval 1 year before. There were 62 eyes of 46 patients seen in the study period later than scheduled (among 144 patients of 183 eyes in total), which represented a larger proportion of delayed patients compared to the previous year (31.9% vs. 14.9%, p<0.0005). Considering the patterns from the control group, the attributed delay due to COVID-19 was 15.0% of patients. The delayed return eyes had a greater decline in BCVA (3 letters), higher rates of worsened OCT results (48%), and prompted reduction in previously prescribed injection intervals (p<0.02).
conclusionThe unintended consequence of delayed care of patients on established care regimens should be anticipated, and mitigate strategies considered if similar restrictions are mandated in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.